A5047305476- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Reproductive Biology and Fertility
- CAR-T cell therapy research
- Lymphoma Diagnosis and Treatment
- Hemoglobinopathies and Related Disorders
- Blood groups and transfusion
- Childhood Cancer Survivors' Quality of Life
- Acute Myeloid Leukemia Research
- Prenatal Screening and Diagnostics
- Chronic Lymphocytic Leukemia Research
- Reproductive Health and Technologies
- Renal and related cancers
- Reproductive System and Pregnancy
- Blood disorders and treatments
- Mycobacterium research and diagnosis
- Pneumocystis jirovecii pneumonia detection and treatment
- Cancer, Hypoxia, and Metabolism
- Pharmaceutical studies and practices
- Safe Handling of Antineoplastic Drugs
- Congenital Diaphragmatic Hernia Studies
- CNS Lymphoma Diagnosis and Treatment
- Tuberculosis Research and Epidemiology
- Polyomavirus and related diseases
- Chronic Myeloid Leukemia Treatments
Assistance Publique – Hôpitaux de Paris
2018-2025
Hôpital Saint-Louis
2016-2025
Hôpital d'instruction des Armées Percy
2022
Université Paris Cité
2018-2021
University of London Institute in Paris
2021
Kiel University
2019
Délégation Paris 5
2018
Sorbonne Paris Cité
2018
Hôpital Cochin
2018
Institut Cochin
2018
Sexual dysfunction and fertility related issues appear as major post-allogeneic hematopoietic stem cell transplantation (HSCT) late effects in young women, with a heavy impact on quality of life. The objective the present study was to evaluate disease treatments sexual life, ovarian function, family planning initiatives context allogeneic HSCT. Between January 2014 2016, adult female patients who underwent HSCT before age 35 had been followed for more than 2 years our center were offered...
Summary Hodgkin lymphoma (HL) is one of the most common cancers in adolescents and young adults (AYA). Paediatric adult therapeutic strategies diverge while sharing objective: maintaining optimal efficacy with less long‐term toxicity. However, few studies have compared outcome AYA treated according to or other approaches. Among 148 patients aged 15–25 years, at Saint‐Louis Hospital for newly diagnosed HL between 2012 2018, 71 were an protocol 77 a paediatric one. The 5‐year overall survival...
Modalities and timing of haematopoietic stem cell transplant (HSCT) in patients with GATA2 deficiency are still subject to debate. On June 2022, 67 (median age 20.6 years) underwent a first allogeneic HSCT among 21 centres. Indications for were myelodysplastic syndrome (MDS) ≤5% blasts ± immunodeficiency (66%), MDS >5% (15%), acute myeloid leukaemia (19%). Conditioning regimen was myeloablative 85% anti-thymocyte globulins used 67%. The cumulative incidence (CInc) graft versus host disease...
<title>Abstract</title> Hodgkin lymphoma (HL) is one of the most common cancers in adolescents and young adults (AYA). Pediatric adult therapeutic strategies diverge while sharing objective: maintaining optimal efficacy with less long-term toxicity. However, few studies have compared outcome AYA treated according to or other approach. Among 148 patients aged 15 25 years, at Saint-Louis Hospital for newly diagnosed HL between 2012 2018, 71 were an protocol 77 a pediatric one. The 5-year OS...
Background: Relapsed/refractory B acute lymphoblastic leukemia (B‐ALL) treatment remains a major challenge. Tisagenlecleucel (CTL019) is chimeric antigen receptor T cell‐ therapy that reprograms autologous cells to target CD19+ cells. This “living drug”, manufactured for each patient, has obtained marketing authorization in 2018 the EU patients under 26 years old refractory ALL, second relapse or more first after allogeneic hematopoietic stem cell transplantation (HSCT). Aims: study reports...